Payment overview · 2025
General Payments
$660.02
26 reported records · 7 companies
Healthcare provider profile · identity verified
Stephanie Laverne Doyle, MD
Allopathic & Osteopathic Physicians|Family Medicine · RIO GRANDE, NJ · NPI 1679747729
Verified facts
What the public records show
CMS Open Payments records show Stephanie Laverne Doyle, MD received $660.02 in general payments during 2025 across 26 reported records.
Novo Nordisk Inc accounted for 34.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $227.50 | 34.5% | 12 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $186.26 | 28.2% | 8 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $114.95 | 17.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.78 | 9.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $42.05 | 6.4% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $19.20 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $9.28 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $660.02 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $186.26 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $119.45 | 2 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $114.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $77.47 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $77.47 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.86 | 7 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $60.78 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $42.05 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $19.20 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $9.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
66 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 534 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 481 | 137 |
| Amlodipine Besylate | Amlodipine Besylate | 446 | 134 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 339 | 103 |
| Lisinopril | Lisinopril | 317 | 102 |
| Metoprolol Succinate | Metoprolol Succinate | 279 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 224 | 71 |
| Omeprazole | Omeprazole | 221 | 67 |
| Metformin Hcl | Metformin Hcl | 182 | 58 |
| Simvastatin | Simvastatin | 177 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 172 | 48 |
| Losartan Potassium | Losartan Potassium | 161 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 157 | 73 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 42 |
| Metformin Hcl Er | Metformin Hcl | 114 | 36 |
| Sertraline Hcl | Sertraline Hcl | 110 | 32 |
| Montelukast Sodium | Montelukast Sodium | 108 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 106 | 31 |
| Pioglitazone Hcl | Pioglitazone Hcl | 106 | 34 |
| Methylprednisolone | Methylprednisolone | 98 | 85 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 97 | 26 |
| Eliquis | Apixaban | 96 | 25 |
| Furosemide | Furosemide | 96 | 34 |
| Trazodone Hcl | Trazodone Hcl | 92 | 28 |
| Clonidine Hcl | Clonidine Hcl | 88 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 25 |
| Gabapentin | Gabapentin | 84 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 82 | 41 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 25 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 69 | 60 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 27 |
| Ozempic | Semaglutide | 66 | 15 |
| Famotidine | Famotidine | 61 | 21 |
| Carvedilol | Carvedilol | 60 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 60 | 16 |
| Allopurinol | Allopurinol | 59 | 17 |
| Azithromycin | Azithromycin | 59 | 52 |
| Januvia | Sitagliptin Phosphate | 59 | 12 |
| Naproxen | Naproxen | 59 | 19 |
| Jardiance | Empagliflozin | 57 | 14 |
| Synthroid | Levothyroxine Sodium | 57 | 21 |
| Ibuprofen | Ibuprofen | 56 | 17 |
| Meloxicam | Meloxicam | 56 | 18 |
| Ezetimibe | Ezetimibe | 55 | 18 |
| Glipizide Er | Glipizide | 53 | 14 |
| Breo Ellipta | Fluticasone/Vilanterol | 52 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 51 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | 13 |
| Potassium Chloride | Potassium Chloride | 46 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 13 |
| Spironolactone | Spironolactone | 42 | 17 |
| Celecoxib | Celecoxib | 41 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Alprazolam | Alprazolam | 38 | 14 |
| Atenolol | Atenolol | 38 | 12 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Baclofen | Baclofen | 37 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Donepezil Hcl | Donepezil Hcl | 36 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 11 |
| Myrbetriq | Mirabegron | 35 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Valsartan | Valsartan | 35 | 12 |
| Valacyclovir | Valacyclovir Hcl | 33 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Sucralfate | Sucralfate | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | 12 |
| Candesartan Cilexetil | Candesartan Cilexetil | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 12 |
| Meclizine Hcl | Meclizine Hcl | 27 | 15 |
| Azelastine Hcl | Azelastine Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Amoxicillin | Amoxicillin | 16 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $660.02 · 26 records | Novo Nordisk Inc | AIRSUPRA, OTEZLA, Ozempic, PURIFIED CORTROPHIN GEL, REPATHA, Rybelsus, TWIIST, VOQUEZNA, Veozah, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error